The objective of this review is to show the main characteristic of migraine in pregnant women because the pattern of this headache type is common and often modified (frequently had an improvement) during pregnancy. However, a considerable part of pregnant women with migraine needs treatment, and concerns about fetal effects of maternal care are important. Among pregnancy complications, the rate of severe nausea and vomiting, in addition of pre-eclampsia was higher in mothers with migraine. The co-morbid depressive/panic disorders and cardiac dysrhythmias occurred also more frequently in pregnant women with migraine. The Hungarian population-based case-control study showed a higher risk for limb deficiency of children after maternal migraine attacks in the 2nd and/or 3rd gestational month, i.e. the critical period of this group of congenital abnormalities (adjusted OR with 95% CI: 2.5, 1.1-5.8). Most pregnant women had a severe migraine in the Hungarian study, and they were treated mainly dipyrone, aminophenazone, ergotamine, acetylsalicylic acid and propranolol. Among migraine related dug treatments, only the teratogenic effect of higher dose of ergotamine was confirmed which associated with a higher risk for neural-tube defects (OR with 95% CI: 6.9, 2.0-24.2). In addition the use of NSAIDs should avoid during the third trimester due to early closing of ductus arteriosus. The recent antimigraine (triptans) drugs were rarely used, though they have no teratogenic effect. This review provides recommendation for appropriate treatment of migraine during pregnancy.